Alphatec (NASDAQ:ATEC – Free Report) had its price objective cut by HC Wainwright from $24.00 to $20.00 in a research note published on Friday morning,Benzinga reports. They currently have a buy rating on the medical technology company’s stock.
ATEC has been the subject of a number of other reports. BMO Capital Markets lowered shares of Alphatec from an “outperform” rating to a “market perform” rating and set a $8.00 target price for the company. in a research note on Friday, October 30th. Wall Street Zen lowered shares of Alphatec from a “buy” rating to a “hold” rating in a research note on Sunday, October 11th. Canaccord Genuity Group cut their price target on Alphatec from $19.00 to $16.00 and set a “buy” rating on the stock in a report on Friday, October 30th. Stephens initiated coverage on Alphatec in a report on Thursday, July 23rd. They set an “overweight” rating and a $15.00 price target on the stock. Finally, Wells Fargo & Company reduced their price objective on Alphatec from $14.00 to $12.00 and set an “overweight” rating for the company in a research report on Friday, October 30th. Eleven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Alphatec presently has a consensus rating of “Moderate Buy” and an average target price of $15.37.
Get Our Latest Analysis on ATEC
Alphatec Price Performance
Alphatec (NASDAQ:ATEC – Get Free Report) last posted its earnings results on Thursday, October 29th. The medical technology company reported $0.09 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.01). Alphatec had a negative net margin of 10.35% and a negative return on equity of 6,752.24%. The company had revenue of $221.17 million during the quarter, compared to the consensus estimate of $225.16 million. During the same quarter in the previous year, the business posted $0.03 earnings per share. The business’s quarterly revenue was up 12.6% compared to the same quarter last year. As a group, research analysts anticipate that Alphatec will post -0.40 earnings per share for the current year.
Insider Transactions at Alphatec
In related news, Director David Demski acquired 60,000 shares of the business’s stock in a transaction that occurred on Friday, October 30th. The shares were acquired at an average cost of $6.81 per share, for a total transaction of $408,600.00. Following the completion of the purchase, the director directly owned 491,635 shares in the company, valued at $3,348,034.35. This trade represents a 13.90% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Patrick Miles acquired 115,000 shares of Alphatec stock in a transaction that occurred on Thursday, September 10th. The stock was bought at an average cost of $8.81 per share, with a total value of $1,013,150.00. Following the acquisition, the chief executive officer directly owned 5,893,551 shares of the company’s stock, valued at approximately $51,922,184.31. This trade represents a 1.99% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 13.48% of the stock is owned by insiders.
Institutional Trading of Alphatec
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Sterling Capital Management LLC increased its stake in shares of Alphatec by 841.5% during the third quarter. Sterling Capital Management LLC now owns 4,105 shares of the medical technology company’s stock valued at $42,000 after acquiring an additional 3,669 shares during the period. Integrated Wealth Concepts LLC bought a new stake in Alphatec during the second quarter worth approximately $52,000. Allworth Financial LP lifted its position in Alphatec by 82.6% in the second quarter. Allworth Financial LP now owns 6,666 shares of the medical technology company’s stock worth $58,000 after purchasing an additional 3,015 shares during the period. Chicago Partners Investment Group LLC acquired a new stake in Alphatec in the third quarter worth approximately $112,000. Finally, Lido Advisors LLC acquired a new stake in Alphatec in the first quarter worth approximately $115,000. 66.35% of the stock is currently owned by institutional investors.
About Alphatec
Alphatec Holdings, Inc. is a medical technology company focused on developing and marketing products for spine surgery. Its offerings are intended to support the surgical treatment of spinal disorders and include implants, biologics, instruments and access systems, along with technologies designed to assist surgeons during procedures. The company’s product portfolio includes solutions for several surgical approaches and stages of spine care, including systems for planning, accessing and instrumenting the spine.
Further Reading
- Five stocks we like better than Alphatec
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with MarketBeat.com's FREE daily email newsletter.
